Posterior Segment

Areas of Expertise

  • Achromatopsia
  • Choroideremia
  • Cystoid Macular Edema
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Dry Age-Related Macular Degeneration (Dry AMD)
  • Glaucoma & Neuroprotection
  • Leber’s Congenital Amaurosis (LCA)
  • Leber’s Hereditary Optic Neuropathy (LHON)
  • Myopia Progression
  • Proliferative Vitreoretinopathy
  • Retinal Vein Occlusion (Branch [BRVO] and Central [CRVO])
  • Retinitis Pigmentosa
  • Retinoschisis
  • Stargardt’s Disease
  • Uveal Melanoma
  • Uveitis (Anterior, Intermediate, Posterior)
  • Vitreomacular Adhesion
  • Wet Age-Related Macular Degeneration (Wet AMD)

Explore how Ora is accelerating research and developing innovative products for the following indications:

Ora-VNC™ Mobility Courses: Advancing IRD Research
Learn More

Ora-VCF™ Contrast Test:
Dry AMD Model
Learn More

Over the past 40+ years, Ora has played a significant role in the development of marketed ophthalmic products for indications in the posterior segment, or “the back of the eye.”

Ora’s tenured experience in ophthalmology reaches far past the scope of our consulting and clinical trial history. We are the industry leader in both therapeutic experience and drug and device combination products that treat the diseases unique to the posterior segment. In the last five years, we have completed more than 25 trials.

Our expansive track record affords our clinical trials to transcend borders, spanning all geographical markets – most notably, the United States, Europe, and Australia. Ora has the capacity to tailor your clinical trial experience to best suit your goals. Our expansive site network allows us to custom-build the clinical trial to your needs – to ensure your investigator and recruitment prerequisites are met.